Relmada Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell RLMD and other ETFs, options, and stocks.

About RLMD

Relmada Therapeutics, Inc. engages in the development of clinical-stage drugs. The firm's pipeline includes NDV-01 and Sepranolone. 

CEO
Sergio Traversa
CEOSergio Traversa
Employees
17
Employees17
Headquarters
Coral Gables, Florida
HeadquartersCoral Gables, Florida
Founded
2012
Founded2012
Employees
17
Employees17

RLMD Key Statistics

Market cap
449.61M
Market cap449.61M
Price-Earnings ratio
-5.62
Price-Earnings ratio-5.62
Dividend yield
—
Dividend yield—
Average volume
1.63M
Average volume1.63M
High today
$4.74
High today$4.74
Low today
$3.82
Low today$3.82
Open price
$4.70
Open price$4.70
Volume
1.74M
Volume1.74M
52 Week high
$8.00
52 Week high$8.00
52 Week low
$3.07
52 Week low$3.07

Stock Snapshot

The current Relmada Therapeutics(RLMD) stock price is $4.21, with a market capitalization of 449.61M. The stock trades at a price-to-earnings (P/E) ratio of -5.62.

On 2026-11-16, Relmada Therapeutics(RLMD) stock traded between a low of $3.82 and a high of $4.74. Shares are currently priced at $4.21, which is +10.4% above the low and -11.2% below the high.

Relmada Therapeutics(RLMD) shares are trading with a volume of 1.74M, against a daily average of 1.63M.

In the last year, Relmada Therapeutics(RLMD) shares hit a 52-week high of $8.00 and a 52-week low of $3.07.

In the last year, Relmada Therapeutics(RLMD) shares hit a 52-week high of $8.00 and a 52-week low of $3.07.

RLMD News

TipRanks 1d
Relmada Therapeutics Earnings Call Signals Clinical Progress

Relmada Therapeutics Inc ((RLMD)) has held its Q3 earnings call. Read on for the main highlights of the call. Relmada Therapeutics’ earnings call struck a broa...

Investing.com 3d
Earnings call transcript: Relmada Therapeutics narrows loss as cash runway extends in Q3 2026 - Investing.com

...

Earnings call transcript: Relmada Therapeutics narrows loss as cash runway extends in Q3 2026 - Investing.com
Seeking Alpha 3d
Relmada Therapeutics GAAP EPS of -$0.12 beats by $0.02

Earnings News Relmada Therapeutics GAAP EPS of -$0.12 beats by $0.02 Nov 12, 2026, 4:57 PM ET Relmada Therapeutics, Inc. (RLMD) Stock By : Harsh Shukla, SA News...

Relmada Therapeutics GAAP EPS of -$0.12 beats by $0.02

More RLMD News

TipRanks 3d
Relmada Therapeutics Reports Third-Quarter Results and Business Update

Relmada Therapeutics ( (RLMD) ) has issued an update. On November 12, 2026, Relmada Therapeutics reported third-quarter financial results and a business update...

People also own

Based on the portfolios of people who own RLMD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.